A Remarkable Long-Lasting Response to Short Course Cabozantinib Therapy in a Patient with Metastatic Renal Cell Carcinoma

Bramati Annalisa, Moretti Anna, Piva Sheila, Bocci Barbara, Presazzi Arianna, Boido Beatrice, Farina Gabriella and Girelli Serena

Department of Oncology, ASST Fatebenefratelli Sacco, Italy Department of Radiology, ASST Fatebenefratelli Sacco, Italy

^*Correspondance to: Girelli Serena 

 PDF  Full Text Case Report | Open Access

Abstract:

In this paper, we report the case of a patient with metastatic renal cell carcinoma who was treated with cabozantinib in a third line setting for 2 weeks and experienced an asymptomatic but severe cardiac impairment, with a decrease of the cardiac Left Ventricular Ejection Fraction (LVEF). This event caused the discontinuation of cabozantinib but surprisingly, despite the short period on treatment, the first disease evaluation performed 3 months later showed a remarkable partial remission of the disease. Moreover, from June 2017 to January 2019 the patient underwent several follow-up CT scans which confirmed the disease response which lasted over 2 years despite never having resumed treatment with cabozantinib.

Keywords:

Cite the Article:

Annalisa B, Anna M, Sheila P, Barbara B, Arianna P, Beatrice B, et al. A Remarkable Long-Lasting Response to Short Course Cabozantinib Therapy in a Patient with Metastatic Renal Cell Carcinoma. Clin Oncol. 2020; 5: 1747.